Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG)
Makaleler > Tam Makale · 2025
Yazarlar: FATİH KUŞ, HASAN ÇAĞRI YILDIRIM, DOĞAN BAYRAM, ÖZNUR BAL, GÖKHAN ŞAHİN, MUZAFFER UĞRAKLI, ATİKE GÖKÇEN DEMİRAY, ÖZKAN ALAN, ILGIN KOÇ, fırat Sirvan, NİLGÜN YILDIRIM, OLÇUN ÜMİT ÜNAL, ŞENDAĞ YASLIKAYA, ELİF ŞAHİN, TEOMAN ŞAKALAR, FATİH ATALAH, OĞUR KARHAN, SERKAN ENKİ, SAADETTİN KILIÇKAP, SERKAN AKIN
JOURNAL OF CHEMOTHERAPY, SCI Expanded İndekslerine Giren Dergi, Uluslararası, PubMed, 2025, ss 1-9
DOI: 10.1080/1120009X.2025.2557678
Özet
BACKGROUND: Well-differentiated (WDLPS) and dedifferentiated liposarcomas (DDLPS) are subtypes with distinct behaviors, often driven by CDK4 amplification. While CDK4/6 inhibitors such as palbociclib show promise in trials, real-world data are scarce. METHODS: We retrospectively analyzed 21 patients with advanced WDLPS or DDLPS treated with palbociclib monotherapy at 16 Turkish Oncology Group centers (2019-2022). Outcomes included progression-free survival (PFS), overall survival (OS), response, and safety. RESULTS: Median age was 51 years; 38.1% had WDLPS and 61.9% DDLPS. Median PFS was 5.3 months and OS 9.1 months. The objective response rate was 0%, but disease control was achieved in 57.1%. WDLPS and earlier-line use were associated with numerically longer OS. Adverse events occurred in 71.4%, most often anemia (52.4%) and neutropenia (33.3%). CONCLUSION: Palbociclib showed modest activity with disease stabilization in some patients, highlighting the need for biomarker-driven and combination strategies.